Although still relatively uncommon in Western countries, esophageal cancer is fatal in the vast majority of cases. In the United States, an estimated...
More »Despite limitations, this study lends some reassurance that risk of osteoporosis is not likely to overshadow the benefit of proton pump inhibitors in...
More »Adding the chemotherapy docetaxel to active symptom control in advanced esophagogastric adenocarcinoma improves survival of patients. These are the...
More »Esophageal cancer generally has a poor prognosis; while preoperative chemotherapy is recommended, tumors often do not respond to treatment.
More »Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in...
More »Dr. Krasna has written an overview of multimodality therapy in esophageal cancer, with a particular focus on aspects related to staging and surgical...
More »Esophageal adenocarcinoma (EAC) affects approximately 11,000 persons per year in the United States, is increasing in incidence, and is associated with...
More »Esophagitis is a known adverse effect of bisphosphonate use and reflux esophagitis is an established risk factor for esophageal cancer through the...
More »Meeting podcast: Listen to nationally regarded GI cancer specialist and clinical researcher, Peter C. Enzinger, MD, Assistant Professor of Medicine,...
More »Although still relatively uncommon in Western countries, esophageal cancer is fatal in the vast majority of cases. In the United States, an estimated...
More »
Showing 1 - 10 of 64 results.
Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in management.
